Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This phase Ⅱ study was designed to evaluate the efficacy and safety of endostar combined with
paclitaxel and nedaplatin as first-line therapy in treating patients with recurrent or
metastatic esophageal squamous cell cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Yuhong Li
Treatments:
Albumin-Bound Paclitaxel Endostar protein Endostatins Nedaplatin Paclitaxel